雷帕霉素哺乳动物靶点信号通路及其抑制剂在肝细胞癌治疗中的研究进展

[Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].

作者信息

Li S Z, Xu F, Sun C Q, Xu P

机构信息

Graduate School, Anhui Medical University, Hefei 230032, China.

Beijing Institute of Radiation Medicine, State Key Laboratory of Proteomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, National Engineering Research Center for Protein Drugs, Beijing 102206, China.

出版信息

Zhonghua Gan Zang Bing Za Zhi. 2018 Jan 20;26(1):77-80. doi: 10.3760/cma.j.issn.1007-3418.2018.01.018.

DOI:10.3760/cma.j.issn.1007-3418.2018.01.018

PMID:29804369

Abstract

Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase in the downstream of the phosphatidylinositol 3-kinases (PI3K) family. This kinase plays an important role in the development and progression of hepatocellular carcinoma (HCC). Preclinical data demonstrate that 40%-50% of HCC patients have dysregulated expression of the effectors of the mTOR signaling pathway, and the activation of the mTOR pathway is associated with poorly differentiated tumors, early tumor recurrence, and poor survival/prognosis. This article reviews the research advances in the potential role of the mTOR signaling pathway and its inhibitors in the treatment of HCC.

摘要

雷帕霉素哺乳动物靶点（mTOR）是磷脂酰肌醇3激酶（PI3K）家族下游的一种丝氨酸/苏氨酸蛋白激酶。该激酶在肝细胞癌（HCC）的发生和发展中起重要作用。临床前数据表明，40%-50%的HCC患者mTOR信号通路效应器表达失调，mTOR通路的激活与肿瘤分化差、早期肿瘤复发及生存/预后不良相关。本文综述了mTOR信号通路及其抑制剂在HCC治疗中的潜在作用的研究进展。